Soleno Therapeutics Provides Corporate Update And Reports Second Quarter 2017 Financial Results
REDWOOD CITY, Calif., Aug. 11, 2017 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update and announced financial results for the three and six months ended June 30, 2017.
“Following our recent successful meeting with the FDA, we expect to initiate a Phase III clinical trial of DCCR in Prader-Willi Syndrome by the end of the year,” said Anish Bhatnagar, M.D., Chief Executive Officer of Soleno Therapeutics. “We are in the process of finalizing the design of a Phase III, randomized, double-blind placebo-controlled study that will treat approximately 100 patients. We remain excited about the potential of DCCR to safely and effectively treat this catastrophic disease. We also recently strengthened our balance sheet through the sale of one of our non-strategic subsidiaries, NeoForce.”
“Following our recent successful meeting with the FDA, we expect to initiate a Phase III clinical trial of DCCR in Prader-Willi Syndrome by the end of the year,” said Anish Bhatnagar, M.D., Chief Executive Officer of Soleno Therapeutics. “We are in the process of finalizing the design of a Phase III, randomized, double-blind placebo-controlled study that will treat approximately 100 patients. We remain excited about the potential of DCCR to safely and effectively treat this catastrophic disease. We also recently strengthened our balance sheet through the sale of one of our non-strategic subsidiaries, NeoForce.”